Tocagen Investigator Sponsored Trial (IST) Program

Thank you for your interest in conducting research using our innovative investigational new drug candidates. Our IST program is open to qualified researchers who are interested in conducting their own research in the U.S. Support is provided based on the scientific merit and rigor of proposals and whether it is in alignment with Tocagen's areas of interest.

Please fill out this form and email to **ISTProgram@tocagen.com.** In your email with your form, please also include your CV, references or relevant literature and any supporting documents. Please understand that Tocagen will review all inquiries, but may not be able to fulfill all such interests.

Investigator and Institution Information

Principal Investigator Name: _____

Institution: _____

Address: _____

Email Address: _____

Phone Number: _____

Additional Contact: _____

Email Address: _____

Phone Number: _____

Concept Information

Areas of Interest:

- ○ Combination therapy (approved drugs and drugs in development) and its impact on mechanism of action (MoA) of investigational new drugs Toca 511 & Toca FC in high grade glioma
- ○ Modified scheduling or administration of Toca 511, and Toca FC post-surgery in high grade glioma
- ○ Patients with specific gene mutations/alterations (e.g. IDH1/2 or unmethylated MGMT) or activations in high grade glioma patients
- ○ Other central nervous system (CNS) malignancies (e.g. Leptomeningeal disease, CNS lymphoma, high risk low grade glioma, tumor with H3K27 mutation)
- ○ Preclinical/translation research outside of CNS malignancies that help to better understand the MoA of Toca 511 & Toca FC

Tocagen™

Study Title: _____

_____

Study Type (Clinical/Preclinical): _____

Disease Population: _____

Background and Study Rationale:

Tocagen™

Hypothesis:

Study Design:

Tocagen™

Primary Objective(s):

Secondary Objectives:

Primary Endpoints:

Secondary Endpoints:

Key Inclusion Criteria:

Tocagen™

Key Exclusion Criteria:

Efficacy Assessments:

Safety Assessments:

Other Assessments:

Proposed Statistical Analysis:

Planned Sample Size:

Planned Number of Sites:

Estimated Time to Initiate Study (Defined as First Patient In for Clinical Studies):

Estimated Study Duration (Defined as First Patient In to Last Patient Out for Clinical Studies):

Publication Plan and Estimated Timeline:

Requested Resources

Drug Compound(s): _____

Funding (approximate amount): _____

Regulatory Requirements for Study Initiation (Yes/No)

IND **IRB** **IBC**